Cachexia is a severe complication of cancer that adversely affects the course of the disease,
with currently no effective treatments. It is characterized by a progressive atrophy of skeletal …

Opinion statement Heart failure (HF) is increasingly recognized as the major complication of
chemotherapy regimens. Despite the development of modern targeted therapies such as …

Skeletal muscle, which accounts for approximately 40% of total body weight, is one of the
most dynamic and plastic tissues in the human body and plays a vital role in movement …

Aim Loss of skeletal muscle mass is a common clinical finding in cancer patients. The
purpose of this meta‐analysis and systematic review was to quantify the effect of doxorubicin …

Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility,
increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of …

Breast cancer represents the most commonly diagnosed cancer while neoadjuvant and
adjuvant chemotherapies are extensively used in order to reduce tumor development and …

Doxorubicin is an extensively used anti-neoplastic drug used for solid and hematogenous
cancer since the 1950s, and its usage is limited due to its toxic effects upon various organs …

Recently, it has been discovered that the PEG layer on nanoparticle surface can create
steric hindrance, preventing efficient cellular uptake of PEGylated nanoparticles. Thus, it …

Simple Summary In addition to cancer-related factors, anti-cancer chemotherapy treatment
can drive life-threatening body wasting in a syndrome known as cachexia. Emerging …

Cancer cachexia is a wasting disorder characterised by specific skeletal muscle and
adipose tissue loss. Cancer cachexia is also driven by inflammation, altered metabolic …